Effectiveness and Safety of Indomethacin versus Ibuprofen for the Treatment of Patent Ductus Arteriosus in Preterm Infants

Abstract

Objective To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA.

Study Design A retrospective comparative effectiveness evaluation study was conducted on preterm infants (≤32 weeks) who received indomethacin or ibuprofen for treatment of symptomatic PDA.

Results Of the 124 eligible infants, 54 received indomethacin and 70 received ibuprofen. The overall incidence of medical PDA closure with indomethacin was 37/54 (68.5%) as compared with 42/70 (60%) in the ibuprofen group (p = 0.32). The proportion of infants with surgical PDA ligation was similar between the two groups (18.5% in both the groups). There was no difference in the incidences of acute renal dysfunction, necrotizing enterocolitis stage ≥ 2, spontaneous intestinal perforation, and gastrointestinal bleeding between indomethacin and ibuprofen groups.

Conclusion Ibuprofen is as effective as indomethacin in the treatment of symptomatic PDA in preterm infants. This study also shows that both agents have similar adverse effects and the choice of one agent over the other should be based on local availability and dosing preference.

Keywords

acute renal dysfunction - ibuprofen - indomethacin - patent ductus arteriosus

• References

• 1 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117: 1113-1121
• 2 Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000; 137: 68-72
• 3 Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 1996; 75: F183-F186
• 4 Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126: 605-610
• 5 Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr 1978; 93: 647-651
• 6 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010; (4) CD003481
• 7 Jones LJ, Craven PD, Attia J, Thakkinstian A, Wright I. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011; 96: F45-F52
• 8 Schmidt B, Davis P, Moddemann D , et al; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344: 1966-1972
• 9 Sehgal A. Global shortage and rationing of indomethacin: need to refine approach. J Perinatol 2010; 30: 384-387
• 10 Benitz WE. Learning to live with patency of the ductus arteriosus in preterm infants. J Perinatol 2011; 31 (Suppl. 01) S42-S48
• 11 Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat?. J Perinatol 2010; 30 (Suppl): S31-S37
• 12 Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 2005; 19: 187-193
• 13 Katakam LI, Cotten CM, Goldberg RN, Dang CN, Smith PB. Safety and effectiveness of indomethacin versus ibuprofen for treatment of patent ductus arteriosus. Am J Perinatol 2010; 27: 425-429
• 14 Duzova A, Bakkaloglu A, Kalyoncu M , et al; Turkish Society for Pediatric Nephrology Acute Kidney Injury Study Group. Etiology and outcome of acute kidney injury in children. Pediatr Nephrol 2010; 25: 1453-1461
• 15 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33: 179-201
• 16 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529-534
• 17 Walsh MC, Yao Q, Gettner P , et al; National Institute of Child Health and Human Development Neonatal Research Network. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004; 114: 1305-1311
• 18 Lago P, Bettiol T, Salvadori S , et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002; 161: 202-207
• 19 Van Overmeire B, Smets K, Lecoutere D , et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674-681
• 20 Yeh TF, Luken J, Raval D, Thalji A, Carr I, Pildes RS. Indomethacin treatment in small versus large premature infants with ductus arteriosus. Comparison of plasma indomethacin concentration and clinical response. Br Heart J 1983; 50: 27-30
• 21 Bidiwala KS, Lorenz JM, Kleinman LI. Renal function correlates of postnatal diuresis in preterm infants. Pediatrics 1988; 82: 50-58
• 22 Miall LS, Henderson MJ, Turner AJ , et al. Plasma creatinine rises dramatically in the first 48 hours of life in preterm infants. Pediatrics 1999; 104: e76
• 23 Antonucci R, Cuzzolin L, Arceri A, Dessì A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 2009; 65: 223-230
• 24 Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med 2009; 22 (Suppl. 03) 88-91
• 25 Vieux R, Desandes R, Boubred F , et al. Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol 2010; 25: 267-274